Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
5-fluorouracil (5-FU)
100%
Cisplatin
100%
Phase II Trial
100%
Diffuse Gastric Cancer
100%
95% Confidence Interval
16%
Stomach
11%
Overall Survival
11%
Adenocarcinoma
11%
Progression-free Survival
11%
Overall Response Rate
11%
Time to Treatment Failure
11%
Multivariable
5%
Hazard Ratio
5%
Histology
5%
Chemotherapy
5%
Median Overall Survival
5%
Adverse Events
5%
Treatment-related Mortality
5%
Untreated Patients
5%
Clinical Trials
5%
Performance Status
5%
Gastric Adenocarcinoma
5%
Inpatient Treatment
5%
Accruals
5%
Dose Intensity
5%
Nave
5%
Gastroesophageal Junction
5%
Early Termination
5%
Treatment Regimen
5%
Oral Fluoropyrimidine
5%
Diffuse Type
5%
Treatment Cycle
5%
Treatment Discontinuation
5%
Number of Treatment
5%
Free Time
5%
Treatment-related Adverse Events
5%
Gastric or Gastroesophageal Junction Adenocarcinoma
5%
Medicine and Dentistry
Abdominal Cancer
100%
Cisplatin
100%
Fluorouracil
100%
Phase III Trials
100%
Oral
100%
Overall Survival
16%
Adenocarcinoma
16%
Progression Free Survival
11%
Time to Treatment
11%
Gastroesophageal Junction
11%
Stomach
11%
Adverse Event
11%
Hazard Ratio
5%
Survival Time
5%
Clinical Trial
5%
Chemotherapy
5%
Stomach Adenocarcinoma
5%
Histology
5%
Fluoropyrimidine
5%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
100%
Cisplatin
100%
Fluorouracil
100%
Phase III Trials
100%
Overall Survival
16%
Adenocarcinoma
16%
Adverse Event
11%
Progression Free Survival
11%
Clinical Trial
5%
Stomach Adenocarcinoma
5%
Survival Time
5%
Fluoropyrimidine
5%
Chemotherapy Regimen
5%